187 related articles for article (PubMed ID: 32893954)
1. Acute chest syndrome in the setting of SARS-COV-2 infections-A case series at an urban medical center in the Bronx.
Morrone KA; Strumph K; Liszewski MJ; Jackson J; Rinke ML; Silver EJ; Minniti C; Davila J; Mitchell WB; Manwani D
Pediatr Blood Cancer; 2020 Nov; 67(11):e28579. PubMed ID: 32893954
[TBL] [Abstract][Full Text] [Related]
2. Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection.
Minniti CP; Zaidi AU; Nouraie M; Manwani D; Crouch GD; Crouch AS; Callaghan MU; Carpenter S; Jacobs C; Han J; Simon J; Glassberg J; Gordeuk VR; Klings ES
Blood Adv; 2021 Jan; 5(1):207-215. PubMed ID: 33570644
[TBL] [Abstract][Full Text] [Related]
3. Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19).
Nur E; Gaartman AE; van Tuijn CFJ; Tang MW; Biemond BJ
Am J Hematol; 2020 Jun; 95(6):725-726. PubMed ID: 32267016
[No Abstract] [Full Text] [Related]
4. Successful use of veno-venous extracorporeal membrane oxygenation for acute chest syndrome in a child with sickle cell disease and SARS-CoV-2.
Koh W; Malik P; Whitehead J; Morales DLS; Hayes D
Pediatr Pulmonol; 2022 Apr; 57(4):1096-1099. PubMed ID: 35072359
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Infection Presenting as Acute Chest Syndrome in a Child With Hemoglobin SD-Los Angeles Disease: A Case Report and Review of Literature.
Calderwood S; Sabir A; Rao L; Baker B; Balasa V; Sathi BK
J Pediatr Hematol Oncol; 2023 Mar; 45(2):82-87. PubMed ID: 36162052
[TBL] [Abstract][Full Text] [Related]
6. Description of a national, multi-center registry of patients with sickle cell disease and SARS-CoV-2 infection: Data from the Pediatric COVID-19 United States Registry.
Dain AS; Diorio C; Fisher BT; Hankins JS; Witmer CM; Boustany M; Burton M; Ferrolino J; Sadaf S; Ross HS; Maron G;
Pediatr Blood Cancer; 2024 Jun; 71(6):e30909. PubMed ID: 38469996
[TBL] [Abstract][Full Text] [Related]
7. The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease.
George A; Benton J; Pratt J; Kim MO; Kalinyak KA; Kalfa TA; Joiner CH
Pediatr Blood Cancer; 2011 Oct; 57(4):648-53. PubMed ID: 21360656
[TBL] [Abstract][Full Text] [Related]
8. Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report.
Afana MS; Abu-Tineh M; Alshurafa A; Yasin AK; Ahmed K; Abdulgayoom M; Yassin MA
Hematology; 2023 Dec; 28(1):2229115. PubMed ID: 37519115
[TBL] [Abstract][Full Text] [Related]
9. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab.
De Luna G; Habibi A; Deux JF; Colard M; Pham Hung d'Alexandry d'Orengiani AL; Schlemmer F; Joher N; Kassasseya C; Pawlotsky JM; Ourghanlian C; Michel M; Mekontso-Dessap A; Bartolucci P
Am J Hematol; 2020 Jul; 95(7):876-878. PubMed ID: 32282956
[No Abstract] [Full Text] [Related]
10. Sickle cell disease clinical phenotypes in children from South-Western, Nigeria.
Adegoke SA; Adeodu OO; Adekile AD
Niger J Clin Pract; 2015; 18(1):95-101. PubMed ID: 25511352
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 infection in pediatric patient with hemoglobin SC disease.
Dagalakis U; Hammershaimb E; McArthur MA; Macatangay RA
Pediatr Blood Cancer; 2020 Nov; 67(11):e28430. PubMed ID: 32776470
[No Abstract] [Full Text] [Related]
12. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
13. Care of patients with hemoglobin disorders during the COVID-19 pandemic: An overview of recommendations.
Taher AT; Bou-Fakhredin R; Kreidieh F; Motta I; De Franceschi L; Cappellini MD
Am J Hematol; 2020 Aug; 95(8):E208-E210. PubMed ID: 32394480
[No Abstract] [Full Text] [Related]
14. Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates.
Novelli EM; Kato GJ; Ragni MV; Zhang Y; Hildesheim ME; Nouraie M; Barge S; Meyer MP; Hassett AC; Gordeuk VR; Gladwin MT; Isenberg JS
Am J Hematol; 2012 Mar; 87(3):326-30. PubMed ID: 22318901
[TBL] [Abstract][Full Text] [Related]
15. Long-term clinical outcomes and healthcare utilization of sickle cell disease patients with COVID-19: A 2.5-year follow-up study.
Feit A; Gordon M; Alamuri TT; Hou W; Mitchell WB; Manwani D; Duong TQ
Eur J Haematol; 2023 Oct; 111(4):636-643. PubMed ID: 37492929
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors associated with COVID-19 related severity in sickle cell disease.
Yurtsever N; Nandi V; Ziemba Y; Shi PA
Blood Cells Mol Dis; 2021 Dec; 92():102627. PubMed ID: 34823201
[TBL] [Abstract][Full Text] [Related]
17. Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea.
Singh SA; Koumbourlis AC; Aygun B
Pediatr Blood Cancer; 2008 Jun; 50(6):1258-60. PubMed ID: 18293380
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
19. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
20. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
